Opportunity to invest in Women’s Health:
New medical drug device with pharmacological action for the treatment of Endometriosis, Adenomyosis and Uterine Fibroids

Patent pending

Image

ENDOMETRIOSIS - ADENOMYOSIS - UTERINE FIBROIDS

Image

Endometriosis

Endometriosis is a medical condition where endometrial tissue is found outside the uterus, often accompanied by inflammation. Endometriotic cysts can grow near the bladder, intestines, and peritoneum, irritating surrounding nerves and causing severe pain and discomfort.

Prevalence:

The prevalence of endometriosis is high. According to WHO, approximately 10% of women and girls of reproductive age worldwide are affected. Symptoms often begin in adolescence or the early 20s.

Treatment Market size:

The global market for both endometriosis and adenomyosis treatment is estimated at approximately USD 2,2 billion to USD 2,6 billion in 2026. The market is currently experiencing strong growth, with a projected compound annual growth rate (CAGR) of 11% to 13%. As a result, the total market value is expected to rise to between USD 4.7 billion and USD 6.5 billion by the mid-2030s.

Image

Adenomyosis

Adenomyosis is a disease where the uterus lining grows into the muscular wall, causing the uterus to become enlarged, thickened, and often painful. The symptoms are severe and disruptive, including heavy menstrual bleeding (HMB), severe menstrual cramps, and chronic pelvic pain.

Prevalence:

Estimates of adenomyosis prevalence range widely, depending on the applied diagnostic tool. It is between 10% and 30% of women in their reproductive years and particularly the perimenopausal age group

Treatment Market size:

Adenomyosis is frequently categorized alongside endometriosis. Both are estimated at approximately USD 2,2 billion to USD 2,6 billion in 2026, where adenomyosis specific accounts for USD 0,5 billion USD.

Image

Uterine Fibroids

Uterine fibroids, also known as myomas, are very common, non-cancerous (benign) lumps made of muscle and fibrous tissue that develop in or around the uterus. It is associated with pelvic pain, heavy menstrual bleeding (HMB) and severe menstrual cramps.

Prevalence:

Uterine fibroids are the most common benign tumors of the female reproductive system, with estimates suggesting that 20–80% of women may develop them during their reproductive years or by the age of 50.

Treatment Market size:

The global uterine fibroids treatment market value is large, estimated between USD 4,8 billion and USD 5,4 billion and has a projected compound annual growth rate (CAGR) of 7,6% to 9,7%.

TEAM

Image

Prof. dr. Jasper Verguts
Gynecologist

Dr. Jasper Verguts is a gynecologist at Jessa Hospital in Hasselt, Belgium, where he leads a Centre of Expertise for endometriosis. He is also a visiting-professor at the University of Hasselt in the Faculty of Medicine and Life Sciences.

He is an acknowledged expert, asked in the media, to draw attention to the late diagnosis of endometriosis and adenomyosis and published a series of peer-reviewed scientific papers on this topic.

Image

Dr. Geert Jackers
Materials specialist

Dr. Geert Jackers is a trained chemist and obtained his Ph.D. degree in 2002 at the University of Gent for his work on biodegradable polymers applied in hard tissue engineering (bone regeneration). A research study that was patented.

After that, he worked for many years in several multinational companies as R&D Manager.

In recent years, he was involved in the development of new medical devices for contraception in the life sciences.

Image

Jean Van Nuwenborg
Financial specialist

Jean Van Nuwenborg is an experienced advisor and strategist in the life sciences, with a career spanning over 25 years focused on investments and management in the healthcare sector.

His core expertise in Life Sciences is as an Investment Strategist. He possesses over 20 years of experience in life science investments, specializing in supporting companies in the seed and early growth phases.

PARTNER

Image

INVESTMENT OPPORTUNITY

Patent Pending Technology

New Medical drug device with pharmacological action based on prototypes

Medical Claim: treatment of adenomyosis in this first investment round

What is needed

  • Series A venture capital financing 1,6 million Euro

  • Entitled for government funding of about 55% of the eligible project cost

  • Total budget: 3,5 million Euro

What will be done with the money

  • Establishing the start-up Jackers Pharma Devices in Belgium (Liège area)

  • Formulation finalization and GMP-compliant production at Besins Healthcare PharmTech (based in Liège, Belgium)

  • Phase II proof-of-concept on adenomyosis patients at Jessa University Hospital in Hasselt, Belgium

Future steps – requiring additional investments

  • Phase III clinical trial on adenomyosis patients

  • Market authorization via the EU centralized portal of the medical drug device claiming treatment of adenomyosis

  • Phase II proof-of-concept clinical trial * on adenomyosis patients suffering from endometriosis and uterine fibroids

Support and join our crowdfunding campaign

Link to the full version of the video, click here

Join our crowdfunding campaign

My story

Image

I am Geert, living in Belgium, the driving force behind this crowdfunding campaign and the entire project.

How it all began...

Some time ago, I happened to come into contact for the first time with the devastating impact of the disease endometriosis.

The daughter of a good friend is unfortunately affected by this debilitating illness. It is utterly shocking to witness and experience… Studying has become impossible for this young woman due to the pain and discomfort! Earning her diploma? No certainty! Surgery brought only temporary relief. The horrific symptoms and intense pain came back! Her life is entirely controlled and devastated by this disease. Pain currently dominates her existence. Can we even speak of quality of life in such a case?

Can something be done about this, I wondered? As a scientist specialized in the life sciences, I was deeply moved and compelled by this issue. I began to explore scientific and medical literature.

From this research, a new concept emerged and took shape: a new medicine. In fact, a new therapy — one that brings benefits without the drawbacks of conventional treatments.

THERE IS HOPE!

My search continued. Which gynaecologist would believe in this and be willing to help carry this project? Because I can’t do this alone.

An accessible book about endometriosis revealed the solution: the author!
A gynaecologist and professor affiliated with the University of Hasselt, specialized in the treatment of endometriosis: Dr. Jasper Verguts.

Dr. Verguts was immediately on board, because in his opinion, the concept is both feasible and workable. Positive news!

But of course, this still needs to be proven in practice. How?

Quite simply: by testing it on women suffering from endometriosis. Though in practice, this is not so simple – and especially very expensive!

To be able to test it, the medicine first needs to be produced.

So the next question quickly followed: who can develop this medicine so that we can test it on patients and prove that it truly works? And on top of that, it needs to be manufactured in accordance with all legal and very strict pharmaceutical regulations.

After thorough research, I came across two reliable companies – one based near New York in the United States, and the other, incredibly enough, right here in Belgium! A biotech company from the Liège region, called UniD Manufacturing.

After numerous discussions, it became clear that they could take on this task – but that a significant amount of funding is needed to properly carry out this concept.

 

How much money?

The staggering amount of 1.5 million euros!

The next question was a big one: where am I going to find that much money?

From investors? Those willing to dive into the project and share in the risk by providing seed capital (funding to develop an idea into a prototype — exactly what we aim to do!).

Unfortunately, there was nothing but silence on that front — so silent you could hear a pin drop.

That’s why we’re launching this crowdfunding campaign! It gives us the opportunity to kick off the project and, in the near future, convince investors of the concept by showing that IT CAN BE DONE!

Because yes, a lot of money is needed — too much to be raised through crowdfunding alone.

List of recent scientific publications by Prof. Dr. Jasper Verguts

Image

Prof. Dr. Jasper Verguts is a Belgium gynaecologist at Jessa Hospital in Hasselt, where he leads a centre of expertise for endometriosis. He is also a professor at Hasselt University in the Faculty of Medicine and Life Sciences.

Dr. Jasper Verguts recently wrote a highly accessible book on endometriosis: Recognising and Treating Endometriosis – Jasper Verguts | Standaard Uitgeverij, 2022, ISBN: 9789022338971. - bestellen kan via bol.com

Do you have any questions or would you like to support this project in a concrete way?

Geert Jackers

Email : geert.jackers@polymerinvent.com

BE0847.834.735